DSM Biologics and MorphoSys AG have a Biopharmaceutical Manufacturing Agreement covering process development and cGMP manufacturing of MOR202. MOR202 is a fully human HuCAL® antibody, directed against CD38, a promising target for the treatment of multiple myeloma. DSM Biologics will manufacture MOR202 in its cGMP facilities in Groningen, the Netherlands.
“Based on the positive experiences we have had with the PER.C6® cell line and DSM's manufacturing capabilities for our MOR103 lead program, we have chosen to continue to use this platform for MOR202. Our work with DSM has continued not only because DSM offers the production platform and manufacturing capabilities to meet our current needs, but also because of their level of attention to our projects and commitment to a strong partnership."
Dr. Marlies Sproll
Chief Scientific Officer
MorphoSys
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies.
PER.C6® is a registered trademark of Crucell Holland B.V.
